Antimicrobial resistance (AMR) poses a significant public health and economic challenge, increasing treatment costs and reducing antibiotic effectiveness. This study employs machine learning to analyze genomic and epidemiological data from the public databases for molecular typing and microbial genome diversity (PubMLST), incorporating data from UK government-supported AMR surveillance by the Food Standards Agency and Food Standards Scotland. We identify AMR patterns in Campylobacter jejuni and Campylobacter coli isolates collected in the UK from 2001 to 2017. The research integrates whole-genome sequencing (WGS) data, epidemiological metadata, and economic projections to identify key resistance determinants and forecast future resistance trends and healthcare costs. We investigate gyrA mutations for fluoroquinolone resistance and the tet(O) gene for tetracycline resistance, training a Random Forest model validated with bootstrap resampling (1,000 samples, 95% confidence intervals), achieving 74% accuracy in predicting AMR phenotypes. Time-series forecasting models (SARIMA, SIR, and Prophet) predict a rise in campylobacteriosis cases, potentially exceeding 130 cases per 100,000 people by 2050, with an economic burden projected to surpass 1.9 billion GBP annually if left unchecked. An enhanced Random Forest system, analyzing 6,683 isolates, refines predictions by incorporating temporal patterns, uncertainty estimation, and resistance trend modeling, indicating sustained high beta-lactam resistance, increasing fluoroquinolone resistance, and fluctuating tetracycline resistance.

These were five major works and twelve other works and thus included diverse views of integrating AI in cardiovascular treatment. Synthesis of Results The data obtained was then combined to provide an integrated view on the effect of early detection by AI in the context of CVDs on health care costs and patients. The synthesis was to compare the mostly used diagnosing techniques with the newer AI techniques; the merits and demerits of integration of AI . Ethical Considerations Each of the studies considered within this systematic review complied with ethical procedures applicable for investigation involving human participants. Issues of privacy and security were also discussed particularly where patients' data were involved.

This study reveals the important role of prevention care and medication adherence in reducing hospitalizations. By using a structured dataset of 1,171 patients, four machine learning models Logistic Regression, Gradient Boosting, Random Forest, and Artificial Neural Networks are applied to predict five-year hospitalization risk, with the Gradient Boosting model achieving the highest accuracy of 81.2%. The result demonstrated that patients with high medication adherence and consistent preventive care can reduce 38.3% and 37.7% in hospitalization risk. The finding also suggests that targeted preventive care can have positive Return on Investment (ROI), and therefore ML models can effectively direct personalized interventions and contribute to long-term medical savings.

With U.S. healthcare spending approaching $5T (NHE Fact Sheet 2024), and 25% of it estimated to be wasteful (Waste in the US the health care system: estimated costs and potential for savings, n.d.), the need to better predict risk and optimal patient care is evermore important. This paper introduces the Large Medical Model (LMM), a generative pre-trained transformer (GPT) designed to guide and predict the broad facets of patient care and healthcare administration. The model is trained on medical event sequences from over 140M longitudinal patient claims records with a specialized vocabulary built from medical terminology systems and demonstrates a superior capability to forecast healthcare costs and identify potential risk factors. Through experimentation and validation, we showcase the LMM's proficiency in not only in cost and risk predictions, but also in discerning intricate patterns within complex medical conditions and an ability to identify novel relationships in patient care. The LMM is able to improve both cost prediction by 14.1% over the best commercial models and chronic conditions prediction by 1.9% over the best transformer models in research predicting a broad set of conditions. The LMM is a substantial advancement in healthcare analytics, offering the potential to significantly enhance risk assessment, cost management, and personalized medicine.

Due to rapidly rising healthcare costs worldwide, there is significant interest in controlling them. An important aspect concerns price transparency, as preliminary efforts have demonstrated that patients will shop for lower costs, driving efficiency. This requires the data to be made available, and models that can predict healthcare costs for a wide range of patient demographics and conditions. We present an approach to this problem by developing a predictive model using machine-learning techniques. We analyzed de-identified patient data from New York State SPARCS (statewide planning and research cooperative system), consisting of 2.3 million records in 2016. We built models to predict costs from patient diagnoses and demographics. We investigated two model classes consisting of sparse regression and decision trees. We obtained the best performance by using a decision tree with depth 10. We obtained an R-square value of 0.76 which is better than the values reported in the literature for similar problems.

The healthcare industry is facing increasing demand due to population growth, aging, and the rise of chronic diseases. According to the World Health Organization, the global demand for healthcare services is expected to increase by 15% by 2030. The healthcare industry is also one of the largest and fastest-growing sectors of the global economy, with spending expected to reach $10 trillion by 2022. To meet this demand and improve patient outcomes, healthcare providers are turning to technology. Telemedicine refers to the use of telecommunications and digital technologies to remotely diagnose and treat patients.

Artificial intelligence's (AI) applicability in cardiac imaging is rapidly growing and was a major topic of discussion at this year's EuroPCR 2022 meeting. Many session speakers discussed how they are using AI tools in their day-to-day practice and in their research to improve decision-making and patient/research outcomes. It's no secret, however, that AI tools are only as good as the data sets and the thousands of expert opinions used to power them. Implementing AI applications in our day-to-day practice, from an operations standpoint, could mean adjusting clinician workflows and setting aside time to set up and train on the new systems. And from an efficacy standpoint, it leaves clinicians wary of result accuracy, especially if they are unsure how good the data used to power the technology really is.

Healthcare innovation has helped healthcare providers offer better care and unlock new ways to enhanced treatment for larger population groups. Technology advancements such as Artificial Intelligence and machine learning can offer innovative solutions to the healthcare sector by improving care delivery options and automating tasks that can reduce administrative burden. The Healthcare Innovation Forum discusses how machine learning and AI have revolutionized healthcare through efficient data analysis which has facilitated the decision-making process. By integrating the power of AI and machine learning the healthcare ecosystem can benefit greatly through automation of manual tasks, analyzing large data to improve health outcome levels, and lowering healthcare costs. According to Business Insider, 30% of healthcare costs are related to administrative and operational tasks.

There is no greater challenge for healthcare and life science organizations than ensuring that their digital transformation along with better data management will improve patient outcomes, increase operational efficiency and productivity, and better financial results. The drivers of healthcare and life science's transition from data rich to data driven are not new and include the race to manage cost and improve quality. Some new drivers include the growth of at risk contracting for providers, the threat of care delivery disruption by the retail industry and the impact of drug discovery in the challenge to balance speed to market with costs. Health and life science industries are data rich. IDC estimates that on average, approximately 270 GB of healthcare and life science data will be created for every person in the world in 2020. Transformation of data into insights creates the value for health and life science organizations coupled with organizations establishing a data driven culture.

Healthcare organizations are under consistent, heavy pressure to manage their costs, but patients also have a big role to play in managing healthcare costs by working to take better care of themselves. But what can stakeholders do to get many, if not most, patients to take on that responsibility? That's the question Kumar Srinivas, CTO for the health plan group at NTT DATA, a data management services provider, takes up in a recent commentary at Forbes. In his view, while it's obvious there is little health plans can do to force their patients to improve their preventative health regimens, there are things that can be done to "nudge" them along the same path. He cites a recent book co-authored by an economist and a law professor that describes how people can be "nudged" to make better decisions on a range of personal issues.